Genmab A/S
Close on Nov 18, 2026
Genmab A/S Collaboration Profit-Sharing Revenue by Quarter
Collaboration Profit-Sharing Revenue (Pfizer Tivdak U.S.) ($M)
Genmab A/S Collaboration Profit-Sharing Revenue: $17M in Q3 2026, unchanged from a year earlier.
Where the Q3 2026 figure comes from
“|| Collaboration revenue | 17 | 17 | 53 | 54”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Genmab's 50% share of U.S. Tivdak net profits commercialized with Pfizer; Note 3 also includes $10M one-off license revenue in Q3 2026 alongside reimbursement and milestones below.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up collaboration Profit-Sharing Revenue
Cite this data
StockData. (2026). Genmab A/S Collaboration Profit-Sharing Revenue ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/rev-collaboration
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?